Primary biliary cholangitis: Its science and practice

Lifeng Wang, Christopher Bowlus, Fu Sheng Wang, M. Eric Gershwin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Primary biliary cholangitis (PBC) is an autoimmune liver disorder characterized by progressive destruction of intrahepatic bile ducts, leading to cholestasis, cirrhosis, and liver failure. The etiology of PBC is unknown; however a complex interaction between genetic, environmental, and autoimmune factors is believed to play a role. The major hallmark of PBC is the presence of antimitochondrial antibodies (AMA), with sensitivity and specificity for PBC >90-95%. The immunodominant epitopes recognized by AMA are all mapped within the lipoyl domains of the E2 subunits of the pyruvate dehydrogenase complex (PDC-E2). In addition to autoantibodies, PBC is characterized by an enrichment of autoreactive CD4+ and CD8+ T cells, by enhanced natural killer (NK) cell activity and monocyte responses and accumulation of Th17 cells around damaged bile ducts. Controversial findings regarding numbers and function of regulatory T cells have been reported. The development of several animal models has aided the study and understanding of different aspects of PBC pathogenesis; however no "perfect model" has been developed to date. Novel therapeutic avenues targeting bile acids, nuclear receptors, immune cell receptors, and cytokines have been developed with promising results.

Original languageEnglish (US)
Title of host publicationBiliary Disease
Subtitle of host publicationFrom Science to Clinic
PublisherSpringer International Publishing
Pages129-182
Number of pages54
ISBN (Electronic)9783319501680
ISBN (Print)9783319501666
DOIs
StatePublished - Jan 1 2017

Fingerprint

Cholangitis
T-cells
Liver
Ducts
Pyruvate Dehydrogenase Complex
Immunodominant Epitopes
Cytokine Receptors
Antibodies
Cytoplasmic and Nuclear Receptors
Bile Acids and Salts
Autoantibodies
Animals
Dihydrolipoyllysine-Residue Acetyltransferase
Intrahepatic Bile Ducts
Th17 Cells
Cholestasis
Liver Failure
Regulatory T-Lymphocytes
Bile Ducts
Natural Killer Cells

ASJC Scopus subject areas

  • Medicine(all)
  • Nursing(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Wang, L., Bowlus, C., Wang, F. S., & Gershwin, M. E. (2017). Primary biliary cholangitis: Its science and practice. In Biliary Disease: From Science to Clinic (pp. 129-182). Springer International Publishing. https://doi.org/10.1007/978-3-319-50168-0_8

Primary biliary cholangitis : Its science and practice. / Wang, Lifeng; Bowlus, Christopher; Wang, Fu Sheng; Gershwin, M. Eric.

Biliary Disease: From Science to Clinic. Springer International Publishing, 2017. p. 129-182.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wang, L, Bowlus, C, Wang, FS & Gershwin, ME 2017, Primary biliary cholangitis: Its science and practice. in Biliary Disease: From Science to Clinic. Springer International Publishing, pp. 129-182. https://doi.org/10.1007/978-3-319-50168-0_8
Wang L, Bowlus C, Wang FS, Gershwin ME. Primary biliary cholangitis: Its science and practice. In Biliary Disease: From Science to Clinic. Springer International Publishing. 2017. p. 129-182 https://doi.org/10.1007/978-3-319-50168-0_8
Wang, Lifeng ; Bowlus, Christopher ; Wang, Fu Sheng ; Gershwin, M. Eric. / Primary biliary cholangitis : Its science and practice. Biliary Disease: From Science to Clinic. Springer International Publishing, 2017. pp. 129-182
@inbook{2e4ee4f25e604589b2b32a5ed02d7639,
title = "Primary biliary cholangitis: Its science and practice",
abstract = "Primary biliary cholangitis (PBC) is an autoimmune liver disorder characterized by progressive destruction of intrahepatic bile ducts, leading to cholestasis, cirrhosis, and liver failure. The etiology of PBC is unknown; however a complex interaction between genetic, environmental, and autoimmune factors is believed to play a role. The major hallmark of PBC is the presence of antimitochondrial antibodies (AMA), with sensitivity and specificity for PBC >90-95{\%}. The immunodominant epitopes recognized by AMA are all mapped within the lipoyl domains of the E2 subunits of the pyruvate dehydrogenase complex (PDC-E2). In addition to autoantibodies, PBC is characterized by an enrichment of autoreactive CD4+ and CD8+ T cells, by enhanced natural killer (NK) cell activity and monocyte responses and accumulation of Th17 cells around damaged bile ducts. Controversial findings regarding numbers and function of regulatory T cells have been reported. The development of several animal models has aided the study and understanding of different aspects of PBC pathogenesis; however no {"}perfect model{"} has been developed to date. Novel therapeutic avenues targeting bile acids, nuclear receptors, immune cell receptors, and cytokines have been developed with promising results.",
author = "Lifeng Wang and Christopher Bowlus and Wang, {Fu Sheng} and Gershwin, {M. Eric}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-50168-0_8",
language = "English (US)",
isbn = "9783319501666",
pages = "129--182",
booktitle = "Biliary Disease",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Primary biliary cholangitis

T2 - Its science and practice

AU - Wang, Lifeng

AU - Bowlus, Christopher

AU - Wang, Fu Sheng

AU - Gershwin, M. Eric

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Primary biliary cholangitis (PBC) is an autoimmune liver disorder characterized by progressive destruction of intrahepatic bile ducts, leading to cholestasis, cirrhosis, and liver failure. The etiology of PBC is unknown; however a complex interaction between genetic, environmental, and autoimmune factors is believed to play a role. The major hallmark of PBC is the presence of antimitochondrial antibodies (AMA), with sensitivity and specificity for PBC >90-95%. The immunodominant epitopes recognized by AMA are all mapped within the lipoyl domains of the E2 subunits of the pyruvate dehydrogenase complex (PDC-E2). In addition to autoantibodies, PBC is characterized by an enrichment of autoreactive CD4+ and CD8+ T cells, by enhanced natural killer (NK) cell activity and monocyte responses and accumulation of Th17 cells around damaged bile ducts. Controversial findings regarding numbers and function of regulatory T cells have been reported. The development of several animal models has aided the study and understanding of different aspects of PBC pathogenesis; however no "perfect model" has been developed to date. Novel therapeutic avenues targeting bile acids, nuclear receptors, immune cell receptors, and cytokines have been developed with promising results.

AB - Primary biliary cholangitis (PBC) is an autoimmune liver disorder characterized by progressive destruction of intrahepatic bile ducts, leading to cholestasis, cirrhosis, and liver failure. The etiology of PBC is unknown; however a complex interaction between genetic, environmental, and autoimmune factors is believed to play a role. The major hallmark of PBC is the presence of antimitochondrial antibodies (AMA), with sensitivity and specificity for PBC >90-95%. The immunodominant epitopes recognized by AMA are all mapped within the lipoyl domains of the E2 subunits of the pyruvate dehydrogenase complex (PDC-E2). In addition to autoantibodies, PBC is characterized by an enrichment of autoreactive CD4+ and CD8+ T cells, by enhanced natural killer (NK) cell activity and monocyte responses and accumulation of Th17 cells around damaged bile ducts. Controversial findings regarding numbers and function of regulatory T cells have been reported. The development of several animal models has aided the study and understanding of different aspects of PBC pathogenesis; however no "perfect model" has been developed to date. Novel therapeutic avenues targeting bile acids, nuclear receptors, immune cell receptors, and cytokines have been developed with promising results.

UR - http://www.scopus.com/inward/record.url?scp=85019886978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019886978&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-50168-0_8

DO - 10.1007/978-3-319-50168-0_8

M3 - Chapter

AN - SCOPUS:85019886978

SN - 9783319501666

SP - 129

EP - 182

BT - Biliary Disease

PB - Springer International Publishing

ER -